Want to see ICU full AI Analyst Report?
ICU Stock Chart & Stats
$3.12
$0.04(1.07%)
At close: 4:00 PM EDT
$3.12
$0.04(1.07%)
Day’s Range― - ―
52-Week Range$2.07 - $6.49
Previous CloseN/A
Volume1.09K
Average Volume (3M)165.28K
Market Cap
$13.71M
Enterprise Value$8.16M
Total Cash (Recent Filing)$6.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Nov 18, 2026EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.91
Shares Outstanding4,406,841
10 Day Avg. Volume366,088
30 Day Avg. Volume165,280
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)4.78
Price to Sales (P/S)40.32
P/FCF Ratio-3.66
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue4.77
Enterprise Value/Gross Profit5.14
Enterprise Value/Ebitda-0.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.68
Revenue Forecast (FY)$1.95M
Bulls Say, Bears Say
Bulls Say
Commercial Adoption And Revenue GrowthRevenue growth and expanding use across leading pediatric hospitals indicate early product-market traction. If adoption continues, a broader customer base can support recurring utilization and improve operating leverage, while validating the therapy with influential clinical centers.
Regulatory And Reimbursement ProgressRegulatory clearance for pediatric use and simplified hospital billing reduce barriers to adoption in the current market. Breakthrough designation and a planned adult pathway also strengthen the platform's strategic position, although future expansion still depends on clinical and FDA outcomes.
Clinical Development ProgressSubstantial enrollment in the pivotal trial advances the company toward evidence needed for adult AKI commercialization. Completed registry work, published early patient results, and additional activated sites provide clinical validation and could expand the addressable opportunity if results support approval.
Bears Say
Persistent Cash Burn And UnprofitabilityThe company is consuming substantial cash while generating only modest revenue, so growth currently requires continued funding rather than internally generated resources. Persistent losses can weaken the capital base and constrain investment in trials, commercialization, and other strategic priorities.
Rising Expenses And Declining LiquidityExpense growth is outpacing the company's still-small revenue base, and the cash balance has declined materially within six months. Unless commercialization scales or spending moderates, the resulting runway pressure may force additional financing and divert management attention from execution.
Equity Dilution From FinancingThe sharp increase in shares shows that financing operations has materially diluted existing holders. Continued reliance on equity capital to fund losses and clinical development could further reduce each holder's ownership share and increase the company's dependence on capital-market access.
SeaStar Medical Holding News
ICU FAQ
What was SeaStar Medical Holding’s price range in the past 12 months?
SeaStar Medical Holding lowest stock price was $2.07 and its highest was $6.49 in the past 12 months.
What is SeaStar Medical Holding’s market cap?
SeaStar Medical Holding’s market cap is $13.71M.
When is SeaStar Medical Holding’s upcoming earnings report date?
SeaStar Medical Holding’s upcoming earnings report date is Nov 18, 2026 which is in 28 days.
How were SeaStar Medical Holding’s earnings last quarter?
SeaStar Medical Holding released its earnings results on Aug 12, 2026. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$0.97 by $0.06.
Is SeaStar Medical Holding overvalued?
According to Wall Street analysts SeaStar Medical Holding’s price is currently Overvalued.
Does SeaStar Medical Holding pay dividends?
SeaStar Medical Holding does not currently pay dividends.
What is SeaStar Medical Holding’s EPS estimate?
SeaStar Medical Holding’s EPS estimate is -0.95.
How many shares outstanding does SeaStar Medical Holding have?
SeaStar Medical Holding has 4,406,841 shares outstanding.
What happened to SeaStar Medical Holding’s price movement after its last earnings report?
SeaStar Medical Holding reported an EPS of -$0.91 in its last earnings report, beating expectations of -$0.97. Following the earnings report the stock price went down -5.655%.
Which hedge fund is a major shareholder of SeaStar Medical Holding?
Currently, no hedge funds are holding shares in ICU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SeaStar Medical Holding
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
ICU Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented meaningful commercial and clinical progress: strong year-over-year revenue growth (+82% Q2), expanded hospital adoption (20 of top 50 pediatric centers), important regulatory and reimbursement milestones (Breakthrough Designation, ICD-10-PCS code), and solid enrollment progress in the NEUTRALIZE-AKI pivotal trial (~65.8% enrolled). Offsetting these positives are materially higher operating expenses, a larger net loss in absolute dollars, a notable cash decline (−41.7% from year-end 2025) and an enrollment cadence that is slower than ideal — all of which create near-term execution and funding risks. On balance, the trajectory is encouraging commercially and clinically, but the company must manage cash runway and accelerate enrollment to realize the larger adult opportunity.View all ICU earnings summariesTechnical Analysis
Ownership Overview
3.10% Insiders
1.20% Mutual Funds
<0.01% Other Institutional Investors
94.89% Public Companies and
Individual Investors